The US Patent and Trademark Office(USPTO)has granted two new patents including Patent No.8,252,328 and Patent No.8,252,329 to AcelRx Pharmaceuticals'small-volume oral transmucosal dosage forms.
The 8,252,328 patent covers delivery of sufentanil using NanoTab technology to a homogenous bioadhesive tablet,comprising from about 2.5 to about 100 micrograms of sufentanil and a volume of from about 3 to about 15 microliters.
The 8,252,329 patent also covers the composition of sufentanil NanoTab pain products with claims to a bioadhesive tablet for sublingual administration to a subject comprising from about 2.5 micrograms to about 100 micrograms of sufentanil,a volume of about 0.1 microliters to about 50 microliters.
In addition,AcelRx holds three other US patents which claim both methods and compositions directed to sufentanil containing NanoTabs and provides intellectual property protection in the US through late 2030.
AcelRx president and CEO Richard King said the company has made significant progress in 2012 in establishing its intellectual property portfolio,with five issued US patents now underpinning NanoTab technology.
"We look forward to building on this success through emphasis on the device aspects of our technology platforms as we seek multiple avenues of protection for our proprietary pipeline of product candidates,"King added.
